Macrophages-aPKCɩ-CCL5 Feedback Loop Modulates the Progression and Chemoresistance in Cholangiocarcinoma

[1]  A. Gentilini,et al.  The Role of Stroma in Cholangiocarcinoma: The Intriguing Interplay between Fibroblastic Component, Immune Cell Subsets and Tumor Epithelium , 2018, International journal of molecular sciences.

[2]  T. Ishiko,et al.  Tumour-infiltrating inflammatory and immune cells in patients with extrahepatic cholangiocarcinoma , 2017, British Journal of Cancer.

[3]  Chunsheng Zhang,et al.  Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of CSF1 Receptor Blockade by Inducing PMN-MDSC Infiltration of Tumors. , 2017, Cancer cell.

[4]  Yan Liu,et al.  aPKC‐ι/P‐Sp1/Snail signaling induces epithelial–mesenchymal transition and immunosuppression in cholangiocarcinoma , 2017, Hepatology.

[5]  D. Baltimore,et al.  30 Years of NF-κB: A Blossoming of Relevance to Human Pathobiology , 2017, Cell.

[6]  Jun Ma,et al.  TLR2 promotes human intrahepatic cholangiocarcinoma cell migration and invasion by modulating NF‐κB pathway‐mediated inflammatory responses , 2016, The FEBS journal.

[7]  K. Boberg,et al.  Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA) , 2016, Nature Reviews Gastroenterology &Hepatology.

[8]  Y. Gilad,et al.  Metastasis Suppressors Regulate the Tumor Microenvironment by Blocking Recruitment of Prometastatic Tumor-Associated Macrophages. , 2016, Cancer research.

[9]  S. Turley,et al.  Immunological hallmarks of stromal cells in the tumour microenvironment , 2015, Nature Reviews Immunology.

[10]  G. Natoli,et al.  Macrophages and cancer: from mechanisms to therapeutic implications. , 2015, Trends in immunology.

[11]  S. Fan,et al.  Alternatively activated (M2) macrophages promote tumour growth and invasiveness in hepatocellular carcinoma. , 2015, Journal of hepatology.

[12]  Ying-jian Liang,et al.  Reciprocal activation between ATPase inhibitory factor 1 and NF‐κB drives hepatocellular carcinoma angiogenesis and metastasis , 2014, Hepatology.

[13]  Chun-Hung Chou,et al.  Acetylation of snail modulates the cytokinome of cancer cells to enhance the recruitment of macrophages. , 2014, Cancer cell.

[14]  K. Flaherty,et al.  The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFα. , 2014, Cancer discovery.

[15]  S. Okada,et al.  Aberrant Expression of NF-κB in Liver Fluke Associated Cholangiocarcinoma: Implications for Targeted Therapy , 2014, PloS one.

[16]  B. Li,et al.  Co-delivery of Doxorubicin and Bmi1 siRNA by Folate Receptor Targeted Liposomes Exhibits Enhanced Anti-Tumor Effects in vitro and in vivo , 2014, Theranostics.

[17]  K. Aldape,et al.  Targeting aPKC disables oncogenic signaling by both the EGFR and the proinflammatory cytokine TNFα in glioblastoma , 2014, Science Signaling.

[18]  R. Wong,et al.  Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase , 2014, Oncogene.

[19]  G. Gores,et al.  Desmoplastic stroma and cholangiocarcinoma: Clinical implications and therapeutic targeting , 2014, Hepatology.

[20]  H. Yao,et al.  A positive feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast cancer metastasis. , 2014, Cancer cell.

[21]  M. Lisanti,et al.  CCR5 antagonist blocks metastasis of basal breast cancer cells. , 2012, Cancer research.

[22]  V. Seshan,et al.  A CXCL1 Paracrine Network Links Cancer Chemoresistance and Metastasis , 2012, Cell.

[23]  Jae-Hyun Park,et al.  Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. , 2012, Cancer cell.

[24]  Brian Bierie,et al.  Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma. , 2011, The Journal of clinical investigation.

[25]  G. Gores,et al.  Clinical diagnosis and staging of cholangiocarcinoma , 2011, Nature Reviews Gastroenterology &Hepatology.

[26]  D. Cunningham,et al.  Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. , 2010, The New England journal of medicine.

[27]  Jeffrey W. Pollard,et al.  Macrophage Diversity Enhances Tumor Progression and Metastasis , 2010, Cell.

[28]  R. Huang,et al.  Epithelial-Mesenchymal Transitions in Development and Disease , 2009, Cell.

[29]  A. Fields,et al.  Aurothiomalate Inhibits Transformed Growth by Targeting the PB1 Domain of Protein Kinase Cι* , 2006, Journal of Biological Chemistry.

[30]  M. Karin.  Nuclear factor-kappaB in cancer development and progression. , 2006, Nature.

[31]  M. Diaz-Meco,et al.  The p62 Scaffold Regulates Nerve Growth Factor-induced NF-κB Activation by Influencing TRAF6 Polyubiquitination* , 2005, Journal of Biological Chemistry.

[32]  M. Toi,et al.  Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. , 2005, Nature reviews. Cancer.

[33]  J. Pollard,et al.  A Paracrine Loop between Tumor Cells and Macrophages Is Required for Tumor Cell Migration in Mammary Tumors , 2004, Cancer Research.

[34]  Y. Hirano,et al.  Solution Structure of Atypical Protein Kinase C PB1 Domain and Its Mode of Interaction with ZIP/p62 and MEK5* , 2004, Journal of Biological Chemistry.

[35]  H. Pehamberger,et al.  NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. , 2004, The Journal of clinical investigation.

[36]  G. Bjørkøy,et al.  Interaction Codes within the Family of Mammalian Phox and Bem1p Domain-containing Proteins* , 2003, Journal of Biological Chemistry.

[37]  Michael I. Wilson,et al.  PB1 domain-mediated heterodimerization in NADPH oxidase and signaling complexes of atypical protein kinase C with Par6 and p62. , 2003, Molecular cell.

[38]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[39]  M. Weil,et al.  The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity. , 2002, Cancer research.

[40]  J. Hiscott,et al.  Regulation of RANTES Chemokine Gene Expression Requires Cooperativity Between NF-κB and IFN-Regulatory Factor Transcription Factors1 , 2000, The Journal of Immunology.

[41]  H. Nakano,et al.  The atypical PKC‐interacting protein p62 channels NF‐κB activation by the IL‐1–TRAF6 pathway , 2000, The EMBO journal.

[42]  M. Vandenplas,et al.  Overexpression of atypical PKC in PC12 cells enhances NGF-responsiveness and survival through an NF-κB dependent pathway , 1999, Cell Death and Differentiation.

[43]  A. Fields,et al.  Atypical Protein Kinase C ι Protects Human Leukemia Cells against Drug-induced Apoptosis* , 1997, The Journal of Biological Chemistry.

[44]  R. Glazer,et al.  Liposome-mediated modulation of multidrug resistance in human HL-60 leukemia cells. , 1992, Journal of the National Cancer Institute.